Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
Safety and Efficacy of Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lihua Duan, MD
- Phone Number: 0791-86895639
- Email: lh-duan@163.com
Study Contact Backup
- Name: Jiao Luo, MD
- Phone Number: 0791-86895639
- Email: luojiao02@163.com
Study Locations
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or non-pregnant、non-nursing female.
- Age 18 to 75 years at the time of signing informed consent.
- Fulfilling 2017 ACR/EULAR IIMs classification criteria for DM or ADM.
- Disease activity with skin damage (CDASI ≥12) despite treatment with corticosteroids, immunosuppressive agents or biologics for more than 3 months.
- Written informed consent obtained before taking part in the study.
Exclusion Criteria:
- Pregnant women or breastfeeding mothers, Male and female patients with recent fertility requirements.
- Skin and mucosal lesions should exclude erythema multiforme, syphilis, Sweet disease, Stevens-Johnson syndrome, acne vulgaris, herpes simplex infection, periodic granulocytopenia, and acquired immunodeficiency.
- Severe Concomitant disease: including heart failure (≥level Ⅲ, NYHA), respiratory failure, myelosuppression (WBC<3.0×109/L or N<1.5×109/L, HGB≤85g/L, PLT<100×109/L), peripheral neuropathy.
- Acute severe infections such as sepsis and cellulitis, active hepatitis B or C virus infection, active tuberculosis, and history of a positive test for, or any clinical suspicion of, human immunodeficiency virus (HIV).
- Patients with risk factors for myocardial infarction (including a history of thrombosis), hypercoagulability, or with history of venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
- Patients with allergies or contraindications to lenalidomide or thalidomide.
- Uncontrolled or rapidly progressive myositis or interstitial lung disease at the discretion of the investigator which is likely to warrant escalation in therapy beyond permitted background medications.
- Recurrent or chronic bacterial, viral, fungal, mycobacterial, or other infections including HIV.
- History of recurrent herpes zoster, disseminated (multi-dermatomal) herpes zoster, disseminated herpes simplex or ophthalmic zoster. Herpes zoster lesions within 90 days prior to screening.
- Primary or secondary immunodeficiency.
- Current uncontrolled renal, gastrointestinal, endocrine, pulmonary, cardiac, or neurologic disease, which, in the opinion of the investigator, might place the patient at unacceptable risk for participation in this study.
- History of alcohol, drug, or chemical abuse within one year prior to signing the informed consent form.
- Major surgery within 8 weeks prior to Screening or planned major surgery at any time during participation in the study.
- Immunization with a live/attenuated vaccine within 4 weeks prior to Screening.
- History of malignant tumor within 5 years prior to screening (stable disease for more than 6 months after completion of tumor treatment program can be enrolled).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention with lenalidomide
All subjects will be treated with lenalidomide 5mg/day.
|
All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cutaneous Disease Activity Severity Index (CDASI) activity score
Time Frame: 24 weeks
|
Change in Cutaneous Disease Activity Severity Index (CDASI) activity score (0-100), higher scores mean a worse outcome
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cutaneous Disease Activity Severity Index (CDASI) activity score
Time Frame: 12 weeks
|
Change in Cutaneous Disease Activity Severity Index (CDASI) activity score (0-100), higher scores mean a worse outcome
|
12 weeks
|
|
International Myositis Assessment & Clinical Studies Group (IMACS) Disease Activity Core Set Measures
Time Frame: 12 weeks and 24 weeks
|
Change in International Myositis Assessment & Clinical Studies Group (IMACS) Disease Activity Core Set Measures
|
12 weeks and 24 weeks
|
|
SF-36
Time Frame: 12 weeks and 24 weeks
|
Change in SF-36
|
12 weeks and 24 weeks
|
|
Dermatology Life Quality Index (DLQI)
Time Frame: 12 weeks and 24 weeks
|
Change in Dermatology Life Quality Index (DLQI)
|
12 weeks and 24 weeks
|
|
Adverse event
Time Frame: 24 weeks
|
Adverse event monitoring
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lihua Duan, MD, Jiangxi Provincial People's Hopital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Skin Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Polymyositis
- Myositis
- Dermatomyositis
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
Other Study ID Numbers
- DLH88086
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.